Damora Therapeutics, Inc. (DMRA)
NASDAQ: DMRA · Real-Time Price · USD
23.70
+1.84 (8.42%)
Nov 6, 2026, 4:00 PM EST - Market closed
Damora Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 349.66 | 257.62 | 14.18 | 21.47 | 32.79 | 62.56 |
Short-Term Investments | 178.82 | - | - | 11.69 | 27.44 | 37.63 |
Cash & Short-Term Investments | 528.48 | 257.62 | 14.18 | 33.15 | 60.22 | 100.19 |
Cash Growth | 6848.17% | 1717.45% | -57.24% | -44.95% | -39.89% | -38.75% |
Other Receivables | 0.84 | 0.9 | 0.88 | 1.72 | 1.38 | 2.28 |
Receivables | 0.84 | 0.9 | 0.88 | 1.72 | 1.38 | 2.28 |
Prepaid Expenses | 0.07 | 0.58 | 0.59 | 0.77 | 0.81 | 1.73 |
Other Current Assets | 1.93 | 1.32 | 1.19 | 1.13 | 1.5 | 5.9 |
Total Current Assets | 531.32 | 260.42 | 16.84 | 36.77 | 63.91 | 110.1 |
Property, Plant & Equipment | 0.83 | 0.1 | 0.13 | 0.33 | 1.17 | 1.04 |
Long-Term Investments | - | - | - | - | 5.83 | 9.05 |
Other Long-Term Assets | 0.48 | - | 0.16 | 1.13 | 2.28 | 2.03 |
Total Assets | 532.63 | 260.53 | 17.13 | 38.23 | 73.19 | 122.22 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 6.08 | 17.67 | 0.38 | 1.7 | 3.35 | 1.53 |
Accrued Expenses | 17.04 | 0.72 | 0.32 | 1.67 | 6.74 | 2.18 |
Current Portion of Leases | 0.15 | 0.02 | 0.01 | 0.18 | 0.48 | 0.4 |
Other Current Liabilities | 12.62 | 1.67 | 0.49 | 2.27 | 0.54 | 0.44 |
Total Current Liabilities | 35.89 | 20.07 | 1.2 | 5.83 | 11.11 | 4.54 |
Long-Term Leases | 0.95 | 0.05 | 0.06 | 0.07 | 0.33 | 0.45 |
Other Long-Term Liabilities | 0.03 | 0.03 | 0.04 | - | - | - |
Total Liabilities | 36.87 | 20.15 | 1.3 | 5.9 | 11.44 | 4.99 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Additional Paid-In Capital | 944.31 | 310.69 | 291.9 | 288.04 | 279.73 | 273.66 |
Retained Earnings | -578.31 | -487.36 | -277.52 | -256.09 | -217.74 | -156.11 |
Comprehensive Income & Other | -0.23 | 0.8 | 0.1 | 0.38 | -0.24 | -0.32 |
Total Common Equity | 365.76 | -175.87 | 14.47 | 32.33 | 61.75 | 117.22 |
Shareholders' Equity | 495.76 | 240.38 | 15.83 | 32.33 | 61.75 | 117.22 |
Total Liabilities & Equity | 532.63 | 260.53 | 17.13 | 38.23 | 73.19 | 122.22 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1.1 | 0.07 | 0.07 | 0.25 | 0.8 | 0.85 |
Net Cash (Debt) | 527.38 | 257.56 | 14.1 | 32.9 | 65.25 | 108.39 |
Net Cash Growth | 6899.99% | 1726.38% | -57.14% | -49.58% | -39.80% | -33.37% |
Net Cash Per Share | 13.32 | 188.96 | 12.19 | 30.96 | 64.20 | 107.27 |
Filing Date Shares Outstanding | 61.9 | 60.3 | 1.32 | 1.08 | 1.03 | 1.01 |
Total Common Shares Outstanding | 61.9 | 1.6 | 1.32 | 1.08 | 1.03 | 1.01 |
Working Capital | 495.43 | 240.36 | 15.64 | 30.94 | 52.8 | 105.56 |
Book Value Per Share | 5.91 | -110.10 | 10.99 | 29.81 | 60.18 | 116.01 |
Tangible Book Value | 365.76 | -175.87 | 14.47 | 32.33 | 61.75 | 117.22 |
Tangible Book Value Per Share | 5.91 | -110.10 | 10.99 | 29.81 | 60.18 | 116.01 |
Machinery | - | 0.11 | 0.11 | 0.11 | 0.42 | 0.22 |